Literature DB >> 30858171

Homozygosity for CHEK2 p.Gly167Arg leads to a unique cancer syndrome with multiple complex chromosomal translocations in peripheral blood karyotype.

Tamar Paperna1, Nitzan Sharon-Shwartzman1, Alina Kurolap1,2, Yael Goldberg3, Nivin Moustafa1, Yariv Carasso4, Miora Feinstien3, Adi Mory1, Gili Reznick-Levi1, Claudia Gonzaga-Jauregui5, Alan R Shuldiner5, Lina Basel-Salmon3,6,7,8, Yishai Ofran2,4, Elizabeth E Half2,9, Hagit Baris Feldman1,2.   

Abstract

BACKGROUND: Chromosomal instability, as reflected by structural or copy-number changes, is a known cancer characteristic but are rarely observed in healthy tissue. Mutations in DNA repair genes disrupt the maintenance of DNA integrity and predispose to hereditary cancer syndromes.
OBJECTIVE: To clinically characterise and genetically diagnose two reportedly unrelated patients with unique cancer syndromes, including multiorgan tumourogenesis (patient 1) and early-onset acute myeloid leukaemia (patient 2), both displaying unique peripheral blood karyotypes.
METHODS: Genetic analysis in patient 1 included TruSight One panel and whole-exome sequencing, while patient 2 was diagnosed by FoundationOne Heme genomic analysis; Sanger sequencing was used for mutation confirmation in both patients. Karyotype analysis was performed on peripheral blood, bone marrow and other available tissues.
RESULTS: Both patients were found homozygous for CHEK2 c.499G>A; p.Gly167Arg and exhibited multiple different chromosomal translocations in 30%-60% peripheral blood lymphocytes. This karyotype phenotype was not observed in other tested tissues or in an ovarian cancer patient with a different homozygous missense mutation in CHEK2 (c.1283C>T; p.Ser428Phe).
CONCLUSIONS: The multiple chromosomal translocations in patient lymphocytes highlight the role of CHK2 in DNA repair. We suggest that homozygosity for p.Gly167Arg increases patients' susceptibility to non-accurate correction of DNA breaks and possibly explains their increased susceptibility to either multiple primary tumours during their lifetime or early-onset tumourigenesis. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Dna breakage; acute myeloid leukemia; chek2; chromosomal translocations; multi-organ tumorigenesis

Mesh:

Substances:

Year:  2019        PMID: 30858171     DOI: 10.1136/jmedgenet-2018-105824

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  3 in total

Review 1.  Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.

Authors:  Ryan J Stubbins; Sophia Korotev; Lucy A Godley
Journal:  Curr Hematol Malig Rep       Date:  2022-06-08       Impact factor: 4.213

2.  A recurrent pathogenic BRCA2 exon 5-11 duplication in the Christian Arab population in Israel.

Authors:  Hagit Baris-Feldman; Karin Weiss; Gili Reznick Levi; Gal Larom; Vered Ofen Glassner; Nina Ekhilevitch; Nitzan Sharon Swartzman; Tamar Paperna
Journal:  Fam Cancer       Date:  2021-05-17       Impact factor: 2.446

Review 3.  CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate.

Authors:  Lenka Stolarova; Petra Kleiblova; Marketa Janatova; Jana Soukupova; Petra Zemankova; Libor Macurek; Zdenek Kleibl
Journal:  Cells       Date:  2020-12-12       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.